Search

Displaying results 4901 - 4910 of 10000 in total
  1. Drug

    CLX-0921

    go.drugbank.com/drugs/DB05854
    Experimental

    CLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. … It is a pharmacologically active antihyperglycemic agent that acts by increasing peripheral tissue sensitivity to insulin.

  2. Drug

    Oditrasertib

    go.drugbank.com/drugs/DB21526
    Investigational

    Oditrasertib is under investigation in clinical trial NCT05630547 (A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis … Oditrasertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Oditrasertib is a serine/threonine kinase inhibitor.

  3. Drug

    Atrazine

    go.drugbank.com/drugs/DB07392
    Experimental

    Atrazine is a selective triazine herbicide. Inhalation hazard is low and there are no apparent skin manifestations or other toxicity in humans.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU. … Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing

  5. Drug

    Nemtabrutinib

    go.drugbank.com/drugs/DB18866
    Investigational

    Nemtabrutinib is under investigation in clinical trial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/small Lymphocytic … Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)).

  6. Drug

    Garenoxacin

    go.drugbank.com/drugs/DB06160
    Experimental

    Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    TD-0903

    go.drugbank.com/drugs/DB16463
    Investigational

    TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants … with supplemental oxygenation), and NCT04402866 (focused on ALI and lung inflammation associated with COVID-19)

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    Butobarbital

    go.drugbank.com/drugs/DB01353
    ApprovedIllicit

    Butobarbital is a sedative and a hypnotic drug.

  9. Drug

    Omburtamab

    go.drugbank.com/drugs/DB15635
    Investigational

    [A191829] Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases). … [A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers.

  10. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B … TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.

    Categories: Experimental Unapproved Treatments for COVID-19